Cargando…
Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types
The FDA has recently approved a high tumor mutational burden (TMB-high) biomarker, defined by ≥10 mutations/Mb, for the treatment of solid tumors with pembrolizumab, an immune checkpoint inhibitor (ICI) that targets PD1. However, recent studies have shown that this TMB-high biomarker is only able to...
Autores principales: | Sinha, Neelam, Sinha, Sanju, Valero, Cristina, Schäffer, Alejandro A., Aldape, Kenneth, Litchfield, Kevin, Chan, Timothy A., Morris, Luc G.T., Ruppin, Eytan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177633/ https://www.ncbi.nlm.nih.gov/pubmed/35385572 http://dx.doi.org/10.1158/0008-5472.CAN-21-2542 |
Ejemplares similares
-
In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression
por: Sinha, Sanju, et al.
Publicado: (2020) -
Big data in basic and translational cancer research
por: Jiang, Peng, et al.
Publicado: (2022) -
Sex Biases in Cancer and Autoimmune Disease Incidence Are Strongly Positively Correlated with Mitochondrial Gene Expression across Human Tissues
por: Crawford, David R., et al.
Publicado: (2022) -
Pan-Cancer Analysis of Patient Tumor Single-Cell Transcriptomes Identifies Promising Selective and Safe Chimeric Antigen Receptor Targets in Head and Neck Cancer
por: Madan, Sanna, et al.
Publicado: (2023) -
The landscape of receptor-mediated precision cancer combination therapy via a single-cell perspective
por: Ahmadi, Saba, et al.
Publicado: (2022)